Could a Common Antibiotic Help Prevent Vision Loss?

A 45 percent of Americans with type 1 diabetes (T1D) have some stage of diabetic retinopathy, a leading cause of adult blindness caused by blood-vessel changes in the retina. Results from a new clinical trial offer hope that an inexpensive antibiotic could help prevent this eye disease.

JDRF-funded researchers tested whether doxycycline, a commonly prescribed generic antibiotic, could delay or prevent deterioration of certain eye functions that may contribute to diabetic retinopathy.

Thirty patients with T1D received either 50 mg of doxycycline daily or a placebo pill. By the end of the 24-month trial period, half the patients receiving the antibiotic had improved sensitivity in the fovea, a nerve-rich part of the retina. By contrast, none of the placebo group experienced this improvement. Foveal sensitivity is not a measure of visual acuity, but scientists believe it may be a good predictor for diabetic retinopathy damage and vision loss. Further studies are needed to determine whether doxycycline or similar drugs can help T1D patients avoid this serious complication.

LIVING (continued from page 1)

A mid-1980s. She’s keenly aware of her eye health.

Living Life to the Max with T1D

“Diabetes has never stopped me from doing anything I wanted to do,” said Virginia Hartley, a long-time JDRF supporter. In her 40 years with type 1 diabetes (T1D), she’s lived her life to the fullest while managing her disease with confidence and determination.

Now in her 70s, this spry, energetic woman is a world traveler who makes at least one major trip a year. She’s attended the ballet in Rome and savored the exotic culture of Thailand. Managing blood sugar can be challenging in an unfamiliar culture, but Virginia knows how to do it.

“I’m happy I can propel JDRF’s research forward.”

-S Virginia Hartley

She also makes sure she packs extra lancets, insulin, syringes, alcohol swabs—all the supplies she needs to keep her blood sugar under control.

Virginia even walked the Inca Trail to fabled Machu Picchu. The hike through the breathtaking Andean Mountains took several days and included steep climbs and stomach-churning drops. “I just checked my blood sugar and treated it more often,” she said.

TID care then and now

TID care has improved significantly since 1974, when Virginia first developed the disease. Back then, it was hard for her doctor to even determine she had T1D because she was in the “honeymoon stage” and her symptoms were intermittent. For months, Virginia endured periodic knife-like pains in her middle and even suffered a blackout before her doctor finally diagnosed her with it.

After that, she tested her blood sugar using a meter the size of a small typewriter that took 10 minutes to provide results. She took only one shot of long-acting insulin a day.

Today, by contrast, her blood-glucose meter is the size of a cell phone and she uses an insulin pump to manage her blood sugar 24/7. “I can eat when I want to, instead of on a rigid schedule,” said Virginia. “The pump gives me freedom.”

Supporting TID research

A retired occupational therapist, Virginia now provides dog therapy at a nursing home.

(continued on page 4)
Learn More Today!

Return the enclosed reply card to receive your free gift annuity guide.

OR

Visit our website at jdrf.plannedgiving.org to learn about other giving options that may meet your goals.

OR

Contact Alan Berkowitz, National Director of Planned Giving, toll free at 877.533.4483 or plannedgiving@jdrf.org with any questions you have about extending your support into the future.

Help JDRF While Helping Yourself

If you’re looking for a way to support critical T1D research that also provides you with an income, then a charitable gift annuity may be right for you.

In return for your donation to JDRF, you receive guaranteed payments for life. You can arrange to provide income for one or two people, such as yourself and your spouse. You may also enjoy tax benefits. The part of your gift that remains after your lifetime helps JDRF achieve its goal of creating a world without T1D.

The chart below gives you an example of rates and annual payments. If you’d like to receive a free guide that tells you more about this type of estate gift, simply return the enclosed reply card in the envelope provided. The minimum age to establish a JDRF gift annuity is 60.

<table>
<thead>
<tr>
<th>Age</th>
<th>Rate</th>
<th>Annual Payment for $10,000 Gift Annuity</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>4.4%</td>
<td>$450</td>
</tr>
<tr>
<td>65</td>
<td>4.7%</td>
<td>$470</td>
</tr>
<tr>
<td>70</td>
<td>5.1%</td>
<td>$510</td>
</tr>
<tr>
<td>75</td>
<td>5.8%</td>
<td>$580</td>
</tr>
<tr>
<td>80</td>
<td>6.8%</td>
<td>$680</td>
</tr>
<tr>
<td>85</td>
<td>7.8%</td>
<td>$780</td>
</tr>
</tbody>
</table>

*Rates* are provided at the time of publication and are subject to change. Rates may vary due to market conditions.

Encapsulated Cell Therapy Trial Greenlighted by FDA

Several years ago, JDRF partnered with the biotech company ViaCyte to develop an innovative encapsulated cell replacement therapy which could make individuals insulin-independent for up to two years at a time. Now, the first-ever study in people has been cleared by the U.S. Food and Drug Administration (FDA) and is expected to begin enrolling people with type 1 diabetes (T1D) this fall at the University of California San Diego (UCSD).

Known as VC-01™, this experimental treatment is a teabag-like pouch filled with insulin-producing cells that is implanted under the skin. It has the potential to transform the management of T1D. The first group of individuals will be enrolled at UCSD, following which another four or five trial sites will be added and enroll approximately 40 study participants.

JDRF extends a huge "THANK YOU!" to all our supporters who have helped us reach this important milestone. Together, we will reach our goal of a world without T1D.

To learn more, watch our video at jdrf.org/encapsulation.

Meet Derek Rapp, the New President and CEO of JDRF

What’s your personal connection to type 1 diabetes (T1D)?

My wife Emily and I are proud parents to our 20-year-old son Turner who was diagnosed with T1D in 2004. Five other relatives of Emily’s also have the disease, so suffice it to say that we have seen up close and personal the way this disease can impact a person and a family and are passionately committed to curing T1D.

What prior level of involvement did you have with JDRF?

Through my work on the JDRF International Board, as Chair of the Research Committee, and as a member of our Strategic Advisory Committee, I have played an instrumental part in shaping and implementing the research strategy. I’ve helped to oversee the partnerships JDRF has forged to translate research into therapies and treatments that will ultimately be delivered to patients.

What does the recent momentum in T1D research mean for JDRF and the T1D community?

If you look at the number of clinical trials that are active right now, it’s exciting. As we move closer to patient delivery, the resources needed to move from one stage to the next increase exponentially so we must stay the course and focus on raising funds and supporting this potentially life-changing research.

Will JDRF’s vision and focus shift?

Our vision remains clear; our course is set; our strategy is in place; and the passion and determination of our staff and volunteers is unmatched. And this promise we can make: Our drive to create a world without T1D will accelerate every single day.

Several years ago, JDRF partnered with the biotech company ViaCyte to develop an innovative encapsulated cell replacement therapy which could make individuals insulin-independent for up to two years at a time. Now, the first-ever study in people has been cleared by the U.S. Food and Drug Administration (FDA) and is expected to begin enrolling people with type 1 diabetes (T1D) this fall at the University of California San Diego (UCSD). Known as VC-01™, this experimental treatment is a teabag-like pouch filled with insulin-producing cells that is implanted under the skin. It has the potential to transform the management of T1D. The first group of individuals will be enrolled at UCSD, following which another four or five trial sites will be added and enroll approximately 40 study participants.

JDRF extends a huge "THANK YOU!" to all our supporters who have helped us reach this important milestone. Together, we will reach our goal of a world without T1D.

To learn more, watch our video at jdrf.org/encapsulation.
Help JDRF While Helping Yourself

If you’re looking for a way to support critical T1D research that also provides you with an income, then a charitable gift annuity may be right for you.

In return for your donation to JDRF, you receive guaranteed payments for life. You can arrange it to provide income for one or two people, such as yourself and your spouse. You may also enjoy tax benefits. The part of your gift that remains after your lifetime helps JDRF achieve its goal of creating a world without T1D.

The chart below gives you an example of rates and annual payments. If you’d like to receive a free guide that tells you more about this type of estate gift, simply return the enclosed reply card in the envelope provided. The minimum age to establish a JDRF gift annuity is 60.

### Sample Single-Life Gift Annuity Rates*

<table>
<thead>
<tr>
<th>Age</th>
<th>Rate</th>
<th>Annual Payment for $10,000 Gift Annuity</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>4.4%</td>
<td>$4400</td>
</tr>
<tr>
<td>65</td>
<td>4.7%</td>
<td>$4700</td>
</tr>
<tr>
<td>70</td>
<td>5.1%</td>
<td>$5100</td>
</tr>
<tr>
<td>75</td>
<td>5.8%</td>
<td>$5800</td>
</tr>
<tr>
<td>80</td>
<td>6.6%</td>
<td>$6800</td>
</tr>
<tr>
<td>85</td>
<td>7.8%</td>
<td>$7800</td>
</tr>
</tbody>
</table>

*Based on current American Council on Gift Annuities rates, effective as of January 1, 2012. Rates are revised periodically.

OR

Visit our website at jdrf.plannedgiving.org to learn about other giving options that may meet your goals.

OR

Contact Alan Berkowitz, National Director of Planned Giving, toll free at 877.533.4483 or plannedgiving@jdrf.org with any questions you have about extending your support into the future.

Learn More Today!

Return the enclosed reply card to receive your free gift annuity guide.

What’s your personal connection to type 1 diabetes (T1D)?

My wife Emily and I are proud parents to our 20-year-old son Turner who was diagnosed with T1D in 2004. Five other relatives of Emily’s also have the disease, so suffice it to say that we have seen up close and personal the way this disease can impact a person and a family and are passionately committed to curing T1D.

What prior level of involvement did you have with JDRF?

Through my work on the JDRF International Board, as Chair of the Research Committee, and as a member of our Strategic Advisory Committee, I have played an instrumental part in shaping and implementing the research strategy. I’ve helped to oversee the partnerships JDRF has forged to translate research into therapies and treatments that will ultimately be delivered to patients.

What does the recent momentum in T1D research mean for JDRF and the T1D community?

If you look at the number of clinical trials that are active right now, it’s exciting. As we move closer to patient delivery, the resources needed to move from one stage to the next increase exponentially so we must stay the course and focus on raising funds and supporting this potentially life-changing research.

Will JDRF’s vision and focus shift?

Our vision remains clear; our course is set; our strategy is in place; and the passion and determination of our staff and volunteers is unmatched. And this promise we can make: Our drive to create a world without T1D will accelerate every single day.

Encapsulated Cell Therapy Trial Greenlighted by FDA

Several years ago, JDRF partnered with the biotech company ViaCyte to develop an innovative encapsulated cell replacement therapy which could make individuals insulin-independent for up to two years at a time. Now, the first-ever study in people has been cleared by the U.S. Food and Drug Administration (FDA) and is expected to begin enrolling people with type 1 diabetes (T1D) this fall at the University of California San Diego (UCSD).

Known as VC-01™, this experimental treatment is a teabag-like pouch filled with insulin-producing cells that is implanted under the skin. It has the potential to transform the management of T1D. The first group of individuals will be enrolled at UCSD, following which another four or five trial sites will be added and enroll approximately 40 study participants.

JDRF extends a huge “THANK YOU!” to all our supporters who have helped us reach this important milestone. Together, we will reach our goal of a world without T1D!

To learn more, visit our video at jdrf.org/encapsulation.
A retired occupational therapist, Virginia now provides dog therapy at a nursing home. She also sets up two charitable gift annuities with JDRF to help fight T1D. “A charitable gift annuity gives me the extra income I need and I get a tax deduction. It also benefits T1D research,” she said. “It’s a strong motivation if you know someone with T1D.”

JDRF thanks Virginia Hartley for her outstanding generosity.

To learn more about ways to support JDRF, please contact:
JDRF, Office of Planned Giving
26 Broadway, Floor 14, New York, NY 10004 • Toll-Free: 877.533.4483
Email: plannedgiving@jdrf.org • planwithjdrf.org

LIVING (continued from page 1)

She also does canine agility training, a competition where dogs race over courses filled with tunnels, A-frames, seesaws, and other obstacles. Virginia is a loyal JDRF supporter who has taken part in the Walk to Cure Diabetes since the mid-1980s. She’s keenly interested in T1D research and even applied to join a clinical trial on encapsulated islets. She also set up two charitable gift annuities with JDRF to help fight T1D. “A charitable gift annuity gives me the extra income I need and I get a tax deduction. It also benefits T1D research,” she said. “It’s a strong motivation if you know someone with T1D.”

JDRF thanks Virginia Hartley for her outstanding generosity.

Living Life to the Max with T1D

She also makes sure she packs extra lancets, insulin, syringes, alcohol swabs—all the supplies she needs to keep her blood sugar under control.

Virginia even walked the Inca Trail to fabled Machu Picchu. The hike through the breathtaking Andean Mountains took several days and included steep climbs and stomach-churning drops. “I just chucked my blood sugar and treated it more often,” she said.

T1D care then and now

T1D care has improved significantly since 1974, when Virginia first developed the disease. Back then, it was hard for her doctor to even determine she had T1D because she was in the “honeymoon stage” and her symptoms were intermittent. For months, Virginia endured periodic knife-like pains in her middle and even suffered a blackout before her doctor finally diagnosed her with it.

After that, she tested her blood sugar using a meter the size of a small typewriter that took 10 minutes to provide results. She took only one shot of long-acting insulin a day.

Today, by contrast, her blood-glucose meter is the size of a cell phone and she uses an insulin pump to manage her blood sugar 24/7. “I can eat when I want to, instead of on a rigid schedule,” said Virginia. “The pump gives me freedom.”

“I’m happy I can propel JDRF’s research forward.”

“I always have a blood meter and glucose tabs with me because we do a lot of walking and sightseeing,” she explained. “We eat out a lot, so I carry a carbohydrate book. I’m careful since the food is different. I constantly test and correct as needed.”

- Virginia Hartley
The BETA Society is a group of loyal JDRF friends whose commitments help ensure that critical T1D research will continue until we find a cure.

When you include JDRF in your estate plans—by setting up a charitable gift annuity, leaving a gift in your will or trust, or naming us as a beneficiary of a retirement plan or life insurance policy—you become a member of our BETA Society. Members receive a distinctive lapel pin, invitations to research update events, and other special benefits.

If you have included JDRF in your estate plans, please let us know so we can thank you. Simply return the enclosed reply slip in the envelope provided. Or, contact Alan Berkowitz, National Director of Planned Giving, toll-free at 877.533.4483 or aberkowitz@jdrf.org.

In Appreciation

We’re deeply grateful to the following individuals for supporting our life-changing work through bequests realized between July 1, 2013, and June 30, 2014.

Thelma Alk
Helene W. Alley and Reuben E. Alley, Jr.
John S. and Jane C. Bleakly
Emily Bond
Kenneth Buck
Karl J. and Fay Cannon
Marcia Cohn
Hilda Corran
Dade Curtis
Wesley O. Daugherty
Barbara DeFranceaux
Helen Gralton Dwyer
Gilbert Fern
Shirley Fleischer
Harry Fouts
Beverly Friedman
Charles Gibbs, Jr.
Esther E. Glazer
Dallas Kirk Hammond
Ronald Hanzl
John S. Harvey
Elizabeth Irene Jones
Morton Karsh
Kenneth and Nancy Ladd
Audrey Langan
John Levato
Rachel Lippold
Carol Lurie
Gay Mackenzie
Michael J. Mcabee
Florence McConahey
Sidney and Sybil McCullough
Virginia McGuigan
R. Blair McMillin
Thomas C. McNeal
Mary and Eugene Meyers
Olga and Frederick Mittelstadt
Libby Moore
Rita Mosher
Doris Muench
Gregory T. Mullen, Jr.
Ruth Mullet
Barbara Nelson
Ellen O’Donnell
Ingeborg A. Palmer
Victoria Parkins
Ruth Pomroy
Velda Quimby
Peter Rasmussen
Robert Schiesel
Claudine H. Schork
Marian Schuck
Henrietta Smythe
Gloria Spadaro
Evelyn O. Stoudt
Ora Taylor
Joan and Clay Tellman
Margaret Tiesse
William M. Tunno
Carole Velasquez
Velma Vincent
William Vinson
Lillian K. Walker
Harold Weyer

David Williams
James Otis Wiseman

George Wyckoff
Rafael Zeron

JDRF Welcomes New BETA Society Members
July 1, 2013-June 30, 2014

Anonymous (52)
Mary Beth and Jon Allegretti
Lisa and Steve Altman
Jim Anderson
Carl Aridas
Mr. Christopher and Dr. Carrie Arnold
Dulce and Marvin Barofsky
Robert A. Basile
Suzanne Boudreau
Mary Elizabeth Bunzel
Fran Carpentier & Dr. Ira Salom
Heather and Scott Carr
Joshua Chan
Linda Lee Cohen, MD
Mr. and Mrs. William R. Conley
Hal and Kathy Connors
Tanya Conovaloff
Marsha and Ira Coron
Barbara A. Culp
In memory of Garth E. Damaska
Henry D’Auria
Thomas A. Deeny
Brian T. Deeny
Francis Dixon
Sharon and Binem Dizenhuz
Holly Duncan
Marcia Epstein
Tiburon and Adam Erickson
Jacqueline and Dr. David Ettinger
Johnny Felder
Anita Geach and Tony Ferlauto
Amy and Barry Flick
Charles L. Foster
Angela and Steve Fraser
Jim Garard
Debra and Robert Garelick
Jennifer and Eric Geis
Linda Gnall
Nancy and Don Gray
Douglas Neway and Caryn Green
Renee Gregory
Kyler Hale
Carol and Bill Hauke
Kathy and Jim Hipps
Anne Horner
Jeff and Catherine Huge
John B. Hughes
Dr. Mark Kacher and Jim Imholte
May and J. Michael Jensen
Kathleen and Ron Johnson
Gary Kaempfer
Ellen Keller
William Keller
Theresa and Lance Losey
Ryan LaPointe
Ben Leeds
Phyllis Blair Lowrie
Carla M. and Michael K. McMahan
Mary Ellen Menza-Mullin and Frank Mullin
Keith Miller
Thay and Taso Milonas
Mindy and Frank Morgan
Boyd Mudra
Newman Family Trust
Polly and Hank Noble
Cathy and Steve O’Bryan
Nicole and Shawn Oden
Gertrude Peters

Sherry and Stephen Pino
Julie and Michael Polis
Bret Prichard
Joyce and Daniel Reilly
Laura and Bob Roeder
Betsy and Rick Root
Christopher Rose
Donna and Paul Rosenzweig
Paul Ross
Cheryl Rubinton
Fran Carpentier & Dr. Ira Salom
Cheryl and Joe Salvage
Mary Pat and Tom Santel
Russell and Michelle Schaffer
Jayna and Dan Schimberg
Valerie and Greg Schube
Patty and Dan Shick
Shirlee Jean Smolin
Ann and Thomas Snead
Susan and Timothy Snyder
Patricia Stephenson
Barbara Friedman Stout and George Mowatt Stout
DeeDee and Ashok Sudarshan
Linda and Robert Tjossen
Edward Tomek
Suzanne and Sherman Turner
Sheryl Valentine
Dr. and Mrs. Russell Vester
Margaret and Albert Vontz III
Steve Hubbard and Carolann Swanson
Wanda and Del Weisz
Felicia Williams
Madelon and Chris Zegers
Kathryn and William Zegowitz